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Lipid Binding Studies of
Blood Coagulation Factor VIII C1 and C2 Domains
Rachel Blazevic, Serena Wo and P. Clint Spiegel
Department of Chemistry, Western Washington University; Bellingham, WA
Introduction
The blood coagulation protein, factor VIII (FVIII), is a necessary cofactor for factor IXa in the mammalian blood coagulation cascade. To function as a cofactor, FVIII must bind to 
the anionic phosphatidylserine head groups on the surface of platelets localized to the site of injury. Two domains, C1 and C2, are known to be involved in lipid binding, 
however the working model for platelet binding needs to be bolstered by mutational studies to identify the necessary amino acid contacts. This work uses site directed 
mutagenesis, metal affinity column chromatography, and enzyme-linked immunosorbent assays to directly compare the lipid binding affinities of single residue mutants of 
isolated FVIII C1 domain and C2 domain relative to wild type C1 domain and C2 domain. Understanding the role of both residues may further the model of FVIII lipid binding 
and provide the basis for development of more effective therapeutics.
Background
Methods
Results
C1 Domain Mutations C2 Domain Mutations
Conclusions and Future Work
• C2 Domain: R2320 does play a role in membrane binding.
• Thermodynamic stability and proper folding of human C1 and C2 mutants will be measured with circular dichroism and intrinsic tryptophan fluorescence. Proper folding will 
also be confirmed with pull down assays.
• Binding capacity of C1 and C2 mutants for activated platelet surfaces will be measured with enzyme-linked immunosorbent assays (ELISAs) and liposome sedimentation 
assays. 
• Crystallize the C2 domain mutants to understand conformational changes caused by each mutation and elucidate a working model for membrane binding by the C2 domain. 
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Blood Clotting Cascade
Figure 2. Blood 
coagulation cascade. 
Inactive FVIII circulates 
in complex with VWF. 
Following activation by 
Fxa or thrombin, FVIII 
dissociates from VWF 
and binds active 
platelet surfaces. Here 
it serves as a cofactor 
to serine protease FIXa 
in the activation of FX.1
Blood Coagulation Factor VIII
In plasma, FVIII circulates complexed to 
von Willebrand factor (vWf), which 
protects it from rapid degradation. On 
cleavage by thrombin, activated FVIII 
dissociates from vWf, as a heterotrimer 
(A1/A2/A3-C1-C2). 
Heterotrimeric FVIIIa binds to negatively 
charged phospholipids, and participates as 
a cofactor to factor IXa in the factor X 
activating (tenase) complex.
Figure 1. FVIII Crystal Structure.1
Hemophilia A
• Hemophilia A is an X-linked bleeding disorder caused by inactive 
coagulation protein, FVIII. This deficiency affects 1 in 5,000 males 
worldwide and results in bleeding in joints, muscles, and soft tissues.
• 75% of patients receive infusions of concentrated or recombinant 
FVIII product. Recombinant FVIII is produced in eukaryotic cell lines 
and is often genetically engineered to improve stability, secretion 
levels, circulation half life, and decrease immunogenicity. 
• Approximately 20% of hemophilia A patient develop anti-FVIII 
pathogenic antibodies, known as inhibitors, that reduce treatment 
efficacy. 
ELISA
C1 & C2 Domain Mutations
Purification
Figure 6. All proteins were purified by immobilized metal affinity gravity flow 
column chromatography with TALON (cobalt affinity) resin.  Further 
purification achieved with FPLC using a S column. 3
Site Directed Mutagenesis
hC1 R2163H. Lanes: 1, ladder; 2, hC1 
R2163H post IMAC elution; 3, wash II; 
4, wash I; 5, flow through; 6, high 
speed supernatant; 7, crude cell lysate
Figure 5. All mutants were created through site directed 
mutagenesis and confirmed with Sanger sequencing.2
References
1. Shen, Spiegel, et al. Blood (2008), 111: 1240-1247.
2. Original image from Takara Bio Inc.
3. Original image from Takara Bio Inc.
Project Goal:
To assess the importance of the 
four highlighted residues for C1 
and C2 domain stability and 
membrane binding capability.
Hemophilia Severity Moderate Mild Mild Moderate
Factor VIII Clotting 
Percentages
5% 6% ~25% 2-6%
ELISA: hC2 WT v hC2 R2320T binding to PS. 
Reading taken after 2 hours.
arginine
threonine serine
1             2              3           4              5             6              7  
A2
A3
C1
C2
A1
These residues were chosen because of 
their possible interactions with the 
phosphatidyl serine layer of activated 
platelet membranes. 
Figure 3. Lipid binding 
portion of C1 domain.
Arg 2159 and Arg 2163 
residues highlighted.
C1 Mutations:
R2159H
R2163H
C2 Mutations:
R2215A
R2320S
R2320T
Figure 4. Lipid binding 
portion of C2 domain.
Arg 2320 and Arg 2215 
residues highlighted and 
O-phosphatidyl serine 
head group present.
R2163
R2159
O-PS
head groupR2215
R2320
R2320T    R2320S   R2159H   R2163H
Denature double 
stranded plasmid.
Anneal primers. 
Synthesize 
second strand by 
polymerase chain 
reaction (PCR).
Digest methylated 
DNA template 
with dpnI enzyme.
Transform E. coli with 
mutant plasmid to 
propagate plasmids.
Isolate DNA and 
send off for Sanger 
sequencing.
Transform SHuffle B or 
K12 E. coli strain with 
plasmids containing 
proper mutation for 
protein expression.
Data collected from Factor VIII Variant Database
WT
histidine
R2159H                                         R2163H R2215A                                                       R2320S                                                          R2320T
ELISA: hC2 WT v hC2 R2320S binding to PS. 
Reading taken after 1 hour.
In both cases, the 
mutant (R2320T on 
right, R2320S on 
left), bound PS less 
than the WT, 
indicating that 
residue 2320 does 
play a role in platelet 
membrane binding.
Figure 7. Binding affinity of mutant 
proteins to phosphatidyl serine (PS) 
analyzed with an enzyme-linked 
immunosorbent assay (ELISA).
well wall
96-well plate
(1) Lipids 
bound to 
side of wells 
(15% DOPS)
(2) Block 
where lipids 
are not bound 
(1% BSA)
(3) Add protein 
of interest, 
binds to lipids
(4) Add 
detection 
substrate
(Ni-NTA•HRP), 
binds His-tag of 
protein
(5) Add colorimetric 
substrate, reacts 
with HRP
35.859 kDa
1            2            3             4          
hC2 R2215A. Lanes: 1, hC2 R2215A SHuffle 
B post IMAC elution; 2, ladder; 3, hC2 
R2215A SHuffle K12 post IMAC elution; 4, 
hC2 R2215A SHuffle K12 post IMAC elution
35.859 kDa
1               2               3
hC1 R2159H. Lanes: 1, ladder; 
2, nothing; 3, hC1 R2163H post 
IMAC elution
